AU597718B2 - Pharmaceutical composition comprising a phosphodiesterase inhibitor and a thromboxane a2 antagonist - Google Patents

Pharmaceutical composition comprising a phosphodiesterase inhibitor and a thromboxane a2 antagonist Download PDF

Info

Publication number
AU597718B2
AU597718B2 AU78296/87A AU7829687A AU597718B2 AU 597718 B2 AU597718 B2 AU 597718B2 AU 78296/87 A AU78296/87 A AU 78296/87A AU 7829687 A AU7829687 A AU 7829687A AU 597718 B2 AU597718 B2 AU 597718B2
Authority
AU
Australia
Prior art keywords
thromboxane
antagonist
pharmaceutical composition
ethyl
series
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU78296/87A
Other languages
English (en)
Other versions
AU7829687A (en
Inventor
Walter Haarmann
Josef Nickl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Dr Karl Thomae GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Karl Thomae GmbH filed Critical Dr Karl Thomae GmbH
Publication of AU7829687A publication Critical patent/AU7829687A/en
Application granted granted Critical
Publication of AU597718B2 publication Critical patent/AU597718B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU78296/87A 1986-09-13 1987-09-11 Pharmaceutical composition comprising a phosphodiesterase inhibitor and a thromboxane a2 antagonist Ceased AU597718B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3631294 1986-09-13
DE19863631294 DE3631294A1 (de) 1986-09-13 1986-09-13 Neue synergistische kombination bestehend aus einem phosphodiesterase-hemmer und einem thromboxan-a(pfeil abwaerts)2(pfeil abwaerts)-antagonisten und deren verwendung bzw. herstellung

Publications (2)

Publication Number Publication Date
AU7829687A AU7829687A (en) 1988-03-17
AU597718B2 true AU597718B2 (en) 1990-06-07

Family

ID=6309586

Family Applications (1)

Application Number Title Priority Date Filing Date
AU78296/87A Ceased AU597718B2 (en) 1986-09-13 1987-09-11 Pharmaceutical composition comprising a phosphodiesterase inhibitor and a thromboxane a2 antagonist

Country Status (12)

Country Link
EP (1) EP0260527B1 (enExample)
JP (1) JPS6379838A (enExample)
KR (1) KR880003624A (enExample)
AU (1) AU597718B2 (enExample)
DE (2) DE3631294A1 (enExample)
DK (1) DK472487A (enExample)
ES (1) ES2033755T3 (enExample)
GR (1) GR3004969T3 (enExample)
IL (1) IL83872A0 (enExample)
NZ (1) NZ221779A (enExample)
PH (1) PH23553A (enExample)
ZA (1) ZA876806B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0306846A3 (de) * 1987-09-11 1990-05-02 Dr. Karl Thomae GmbH Neue synergistische Kombination bestehend aus einem Phosphodiesterase-Hemmer und einem Thromboxan-A2-Antagonisten und deren Verwendung bzw. Herstellung
US5858694A (en) * 1997-05-30 1999-01-12 Cell Pathways, Inc. Method for identifying compounds for inhibition of cancerous lesions
EP1216037A2 (en) 1999-09-21 2002-06-26 Emory University Methods and compositions for treating platelet-related disorders using mpl pathway inhibitory agents

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU533193B2 (en) * 1979-03-30 1983-11-10 Borg-Warner Corporation Pulse-width modulated inverter system
AU543568B2 (en) * 1980-12-12 1985-04-26 Dr. Karl Thomae Gmbh Quinazoline and pyrido pyrimidine derivatives
AU547792B2 (en) * 1980-12-27 1985-11-07 Dr. Karl Thomae Gmbh Pyrimido(5,4-d)pyrimidines

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4568676A (en) * 1983-11-25 1986-02-04 Thomas Jefferson University Method of inhibiting aggregation using thromboxane synthetase inhibitor in combination with a cyclic AMP phosphodiesterase inhibitor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU533193B2 (en) * 1979-03-30 1983-11-10 Borg-Warner Corporation Pulse-width modulated inverter system
AU543568B2 (en) * 1980-12-12 1985-04-26 Dr. Karl Thomae Gmbh Quinazoline and pyrido pyrimidine derivatives
AU547792B2 (en) * 1980-12-27 1985-11-07 Dr. Karl Thomae Gmbh Pyrimido(5,4-d)pyrimidines

Also Published As

Publication number Publication date
NZ221779A (en) 1990-03-27
DK472487D0 (da) 1987-09-10
KR880003624A (ko) 1988-05-28
JPS6379838A (ja) 1988-04-09
PH23553A (en) 1989-08-25
AU7829687A (en) 1988-03-17
DE3777926D1 (de) 1992-05-07
ZA876806B (en) 1989-05-30
DE3631294A1 (de) 1988-03-24
DK472487A (da) 1988-03-14
EP0260527A3 (en) 1989-08-09
IL83872A0 (en) 1988-02-29
GR3004969T3 (enExample) 1993-04-28
EP0260527B1 (de) 1992-04-01
EP0260527A2 (de) 1988-03-23
ES2033755T3 (es) 1993-04-01

Similar Documents

Publication Publication Date Title
JP2916978B2 (ja) 放出開始制御型製剤
NZ205894A (en) Pharmaceutical compositions containing mopidamol(2,6-bis(diethanolamino)-4-piperidino-pyrimido(5,4-d)pyrimidine)
NL8500856A (nl) Bij opslag stabiele, snel uiteenvallende geperste voortbrengsels van een farmaceutisch werkzame stof alsmede een werkwijze ter vervaardiging ervan.
AU2006295440A1 (en) Capsule formulation of pirfenidone and pharmaceutically acceptable excipients
CZ299749B6 (cs) Synergické farmaceutické kombinace obsahující inhibitor reninu
KR20110086599A (ko) 안티센스 조성물 및 그의 제조 및 사용 방법
EP0278161B1 (en) Ketone derivatives as medicaments for the treatment or prevention of the withdrawal syndrome
US3459850A (en) Sustained-release tablets,a process and a composition for their preparation
EP0275668A2 (en) Use of ketone derivatives in the treatment of cognitive disorders
JPH01100118A (ja) ホスホジエステラーゼ阻害剤及びトロンボキサンａ↓２拮抗剤を含む新規な医薬組成物、その使用及びその製造法
US6333361B1 (en) Pharmaceutical composition containing zafirlukast
JP2000502345A (ja) 鬱病の処置方法
US4719212A (en) Therapeutic agent for memory disturbance
US4434152A (en) Time-release
JP5575927B2 (ja) ペントキシフィリンの便秘の予防または治療における応用
US20240100011A1 (en) Pediatric formulations of ferric citrate
FR2504390A1 (fr) Composition a base de potassium pour combler un deficit de l'organisme en cet element
EP0260527B1 (de) Neue synergistische Kombination bestehend aus einem Phosphodiesterase-Hemmer und einem Tromboxan-A2-Antagonisten und deren Verwendung bzw. Herstellung
RU2084225C1 (ru) Гипотензивное средство
KR20090086128A (ko) 메만틴 약학 조성물
BG64766B1 (bg) Стабилни състави, съдържащи левосимендан и алгинова киселина
NZ207768A (en) Sustained release tablets comprising dipyridamole
US5141949A (en) Method of providing anxiolytic and antipsychotic treatment
AT393962B (de) Synergistische arzneimittelkombination mit einem gehalt an einem phosphodiesterase-hemmer und derenverwendung
US20070298102A1 (en) Extended Release Pharmaceutical Composition of Celecoxib